AR073909A1 - Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende. - Google Patents
Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende.Info
- Publication number
- AR073909A1 AR073909A1 ARP090104017A ARP090104017A AR073909A1 AR 073909 A1 AR073909 A1 AR 073909A1 AR P090104017 A ARP090104017 A AR P090104017A AR P090104017 A ARP090104017 A AR P090104017A AR 073909 A1 AR073909 A1 AR 073909A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- tgfbrii
- extracellular domain
- understands
- fragment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 title 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010094028 Prothrombin Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19869708P | 2008-11-07 | 2008-11-07 | |
| US17036909P | 2009-04-17 | 2009-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073909A1 true AR073909A1 (es) | 2010-12-09 |
Family
ID=41508691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104017A AR073909A1 (es) | 2008-11-07 | 2009-10-19 | Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8147834B2 (enExample) |
| EP (1) | EP2356152A1 (enExample) |
| JP (1) | JP5667067B2 (enExample) |
| KR (1) | KR101283856B1 (enExample) |
| CN (1) | CN102209727B (enExample) |
| AR (1) | AR073909A1 (enExample) |
| AU (1) | AU2009311375B2 (enExample) |
| BR (1) | BRPI0921263A2 (enExample) |
| CA (1) | CA2742961C (enExample) |
| EA (1) | EA025169B1 (enExample) |
| IL (1) | IL211842A (enExample) |
| JO (1) | JO3096B1 (enExample) |
| MX (1) | MX2011004871A (enExample) |
| NZ (1) | NZ591943A (enExample) |
| PA (1) | PA8846101A1 (enExample) |
| SG (1) | SG10201401280TA (enExample) |
| TW (1) | TWI384998B (enExample) |
| WO (1) | WO2010053814A1 (enExample) |
| ZA (1) | ZA201103178B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013007936A (es) * | 2011-01-06 | 2013-08-09 | Glaxo Group Ltd | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta. |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| KR20170074243A (ko) | 2014-10-31 | 2017-06-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 변형된 t 세포의 생성 방법 및 조성물 |
| AU2015380397B2 (en) | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| EP4169942A1 (en) | 2016-03-11 | 2023-04-26 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| AU2017268469C1 (en) * | 2016-05-20 | 2025-01-02 | President And Fellows Of Harvard College | Gene therapy methods for age-related diseases and conditions |
| AR109770A1 (es) * | 2016-10-18 | 2019-01-23 | Lilly Co Eli | ANTICUERPOS DEL RECEPTOR II DE TGF-b |
| US20180207267A1 (en) * | 2017-01-06 | 2018-07-26 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgfb1 inhibitors and use thereof |
| CN106884005A (zh) * | 2017-01-19 | 2017-06-23 | 樊克兴 | 一种结直肠癌抗原特异性t细胞的制备方法 |
| CN111601616A (zh) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | 用于耗尽cd117+细胞的组合物和方法 |
| JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CN107973853B (zh) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| PH12022551527A1 (en) * | 2019-12-24 | 2024-01-29 | Merus Nv | Tgf-beta-rii binding proteins |
| KR102314157B1 (ko) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법 |
| JP2025512025A (ja) * | 2022-04-15 | 2025-04-16 | バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド | 抗ｃｄ４０抗体及びその使用 |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JP4124815B2 (ja) * | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ＴＧＦ−β型受容体ｃＤＮＡおよびその用途 |
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体 |
| US20090186076A1 (en) * | 2006-02-01 | 2009-07-23 | Kazunori Kataoka | Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent |
-
2009
- 2009-10-18 JO JOP/2009/0382A patent/JO3096B1/ar active
- 2009-10-19 PA PA20098846101A patent/PA8846101A1/es unknown
- 2009-10-19 TW TW098135300A patent/TWI384998B/zh not_active IP Right Cessation
- 2009-10-19 AR ARP090104017A patent/AR073909A1/es unknown
- 2009-10-29 JP JP2011534731A patent/JP5667067B2/ja not_active Expired - Fee Related
- 2009-10-29 MX MX2011004871A patent/MX2011004871A/es active IP Right Grant
- 2009-10-29 SG SG10201401280TA patent/SG10201401280TA/en unknown
- 2009-10-29 CA CA2742961A patent/CA2742961C/en not_active Expired - Fee Related
- 2009-10-29 CN CN200980144391.1A patent/CN102209727B/zh not_active Expired - Fee Related
- 2009-10-29 BR BRPI0921263-9A patent/BRPI0921263A2/pt not_active IP Right Cessation
- 2009-10-29 KR KR1020117010399A patent/KR101283856B1/ko not_active Expired - Fee Related
- 2009-10-29 WO PCT/US2009/062450 patent/WO2010053814A1/en not_active Ceased
- 2009-10-29 AU AU2009311375A patent/AU2009311375B2/en not_active Ceased
- 2009-10-29 EA EA201170659A patent/EA025169B1/ru not_active IP Right Cessation
- 2009-10-29 NZ NZ591943A patent/NZ591943A/xx not_active IP Right Cessation
- 2009-10-29 US US12/608,034 patent/US8147834B2/en not_active Expired - Fee Related
- 2009-10-29 EP EP09745224A patent/EP2356152A1/en not_active Withdrawn
-
2011
- 2011-03-21 IL IL211842A patent/IL211842A/en not_active IP Right Cessation
- 2011-04-29 ZA ZA2011/03178A patent/ZA201103178B/en unknown
-
2012
- 2012-02-20 US US13/400,308 patent/US20120177666A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR101283856B1 (ko) | 2013-07-15 |
| MX2011004871A (es) | 2011-07-13 |
| ZA201103178B (en) | 2012-10-31 |
| JO3096B1 (ar) | 2017-03-15 |
| WO2010053814A1 (en) | 2010-05-14 |
| CA2742961A1 (en) | 2010-05-14 |
| KR20110067155A (ko) | 2011-06-21 |
| NZ591943A (en) | 2012-11-30 |
| IL211842A (en) | 2016-09-29 |
| AU2009311375A1 (en) | 2010-05-14 |
| US20100119516A1 (en) | 2010-05-13 |
| CN102209727B (zh) | 2014-07-30 |
| JP5667067B2 (ja) | 2015-02-12 |
| US8147834B2 (en) | 2012-04-03 |
| CA2742961C (en) | 2016-08-30 |
| EA201170659A1 (ru) | 2011-10-31 |
| EA025169B1 (ru) | 2016-11-30 |
| TW201026326A (en) | 2010-07-16 |
| IL211842A0 (en) | 2011-06-30 |
| BRPI0921263A2 (pt) | 2015-08-04 |
| TWI384998B (zh) | 2013-02-11 |
| AU2009311375B2 (en) | 2014-07-31 |
| CN102209727A (zh) | 2011-10-05 |
| JP2012508170A (ja) | 2012-04-05 |
| SG10201401280TA (en) | 2014-05-29 |
| US20120177666A1 (en) | 2012-07-12 |
| EP2356152A1 (en) | 2011-08-17 |
| PA8846101A1 (es) | 2010-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073909A1 (es) | Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende. | |
| UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
| PH12018501419B1 (en) | Pharmaceutical composition comprising bispecific antibody constructs | |
| CY1118691T1 (el) | Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης | |
| AR074756A1 (es) | Anticuerpos contra la angiopoyetina-2 humana | |
| NO20081883L (no) | Modulasjon av glukokortikoidreseptorekspresjon | |
| BR112012005970A2 (pt) | moduladores tricíclicos de proteína quinase | |
| CR11005A (es) | Formulaciones estables de anticuerpos | |
| BRPI0906404B8 (pt) | construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno | |
| EA200900403A1 (ru) | Соединения, которые модулируют рецептор св2 | |
| EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| MX2011007101A (es) | Composiciones de hidrolizados proteicos que tienen capacidad mejorada para liberar colecistocinina (cck). | |
| EA201200019A1 (ru) | Соединения, которые селективно модулируют рецептор св2 | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| TN2010000169A1 (en) | Molecules and methods for modulating complement component | |
| EA201100523A1 (ru) | Соединения сульфонила, которые селективно модулируют рецептор св2 | |
| PE20150212A1 (es) | Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados | |
| PE20091655A1 (es) | Farmaco para el cancer de higado | |
| BR112016022742A2 (pt) | composições e métodos para modular a expressão de receptor de hormônio do crescimento | |
| CL2012000508A1 (es) | Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas. | |
| CL2007002879A1 (es) | Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |